AU2002221112A1 - Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme - Google Patents

Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme

Info

Publication number
AU2002221112A1
AU2002221112A1 AU2002221112A AU2111202A AU2002221112A1 AU 2002221112 A1 AU2002221112 A1 AU 2002221112A1 AU 2002221112 A AU2002221112 A AU 2002221112A AU 2111202 A AU2111202 A AU 2111202A AU 2002221112 A1 AU2002221112 A1 AU 2002221112A1
Authority
AU
Australia
Prior art keywords
administration
expression
irinotecan
adverse drug
drug reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221112A
Inventor
Yu-Uichi Ando
Yoshinori Hasegawa
Kaoru Shimokata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagoya Industrial Science Research Institute
Original Assignee
Nagoya Industrial Science Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya Industrial Science Research Institute filed Critical Nagoya Industrial Science Research Institute
Publication of AU2002221112A1 publication Critical patent/AU2002221112A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan; and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drug reaction , thereby reducing the adverse drug reaction cased by the administration of irinotecan. <IMAGE>
AU2002221112A 2000-12-12 2001-12-10 Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme Abandoned AU2002221112A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000376756 2000-12-12
JP2000-376756 2000-12-12
PCT/JP2001/010813 WO2002048400A1 (en) 2000-12-12 2001-12-10 Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate, by ugt1a1 enzyme

Publications (1)

Publication Number Publication Date
AU2002221112A1 true AU2002221112A1 (en) 2002-06-24

Family

ID=18845576

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221112A Abandoned AU2002221112A1 (en) 2000-12-12 2001-12-10 Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme

Country Status (10)

Country Link
US (4) US20040058363A1 (en)
EP (1) EP1352970B1 (en)
JP (2) JP4447835B2 (en)
KR (2) KR101651391B1 (en)
CN (1) CN100374575C (en)
AT (1) ATE469966T1 (en)
AU (1) AU2002221112A1 (en)
DE (1) DE60142309D1 (en)
ES (1) ES2346848T3 (en)
WO (1) WO2002048400A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
WO2002059375A2 (en) * 2001-01-26 2002-08-01 University Of Chicago Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
CA2505410A1 (en) * 2002-09-20 2004-04-01 Universite Laval Method for determining the predisposition of patients to toxicity or lack of efficacy of a drug
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
US7807350B2 (en) 2003-05-30 2010-10-05 The University Of Chicago Methods for predicting irinotecan toxicity
MXPA06003826A (en) * 2003-10-06 2006-06-14 Novartis Ag Biomarkers for the prediction of drug-induced diarrhoea.
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
JPWO2007055261A1 (en) * 2005-11-10 2009-04-30 財団法人新産業創造研究機構 UGT1A1 gene polymorphism testing method
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
GB2432365A (en) * 2005-11-18 2007-05-23 Dxs Ltd A nucleic acid molecule for detecting polymorphisms in the UGT1A1 promoter
JP4884899B2 (en) * 2006-09-19 2012-02-29 東洋鋼鈑株式会社 Method for determining risk of occurrence of side effects of irinotecan and kit therefor
WO2008066136A1 (en) * 2006-11-30 2008-06-05 Arkray, Inc. Primer set for amplification of ugt1a1 gene, reagent for amplification of ugt1a1 gene comprising the same, and use of the same
KR200452078Y1 (en) * 2009-03-10 2011-01-28 주식회사 디아이디 Handle for wallpaper sample book
JP2011250726A (en) * 2010-06-01 2011-12-15 Toyo Kohan Co Ltd Method for determining potential risk of side effect of irinotecan, and kit therefor
CN102816858B (en) * 2012-09-06 2014-02-19 上海源奇生物医药科技有限公司 Primer, probe and kit thereof for detecting UGT1A1 genotypes
JP6324828B2 (en) * 2014-07-07 2018-05-16 株式会社日立製作所 Medicinal effect analysis system and medicinal effect analysis method
CN107208163B (en) 2015-02-17 2021-01-08 国立大学法人山口大学 Method for aiding in the prediction of the risk of occurrence of irinotecan side-effects
CN107043808A (en) * 2017-01-19 2017-08-15 上海赛安生物医药科技有限公司 UGT1A1 genetic polymorphism detection primer peptide nucleic acids and its kit
CN109371127A (en) * 2018-10-22 2019-02-22 江苏美因康生物科技有限公司 The kit and method of a kind of while quick detection UGT1A1*6 type and UGT1A1*28 type gene pleiomorphism

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
WO1997032042A2 (en) * 1996-03-01 1997-09-04 The University Court Of The University Of Dundee Drug trial assay system
PT1071710E (en) * 1998-04-15 2007-01-31 Serono Genetics Inst Sa Genomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma
EP1084271A2 (en) * 1998-05-07 2001-03-21 Axys Pharmaceuticals, Inc. Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter

Also Published As

Publication number Publication date
KR20030053064A (en) 2003-06-27
KR20160031023A (en) 2016-03-21
JP4616919B2 (en) 2011-01-19
EP1352970A4 (en) 2004-08-25
US20040058363A1 (en) 2004-03-25
WO2002048400A1 (en) 2002-06-20
ATE469966T1 (en) 2010-06-15
EP1352970B1 (en) 2010-06-02
US20110151474A1 (en) 2011-06-23
CN100374575C (en) 2008-03-12
CN1547613A (en) 2004-11-17
DE60142309D1 (en) 2010-07-15
JPWO2002048400A1 (en) 2004-04-15
JP2009195247A (en) 2009-09-03
EP1352970A1 (en) 2003-10-15
KR101651287B1 (en) 2016-08-26
KR101651391B1 (en) 2016-08-25
US20070082357A1 (en) 2007-04-12
JP4447835B2 (en) 2010-04-07
US20090263818A1 (en) 2009-10-22
ES2346848T3 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
AU2002221112A1 (en) Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate,by ugt1a1 enzyme
Innocenti et al. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes
WO2003038123A3 (en) Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene
YU74500A (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
WO2001090122A3 (en) Haplotypes of the ctla4 gene
WO2002038589A3 (en) Haplotypes of the cyp2d6 gene
WO2002006294A3 (en) Haplotypes of the mmp13 gene
WO2001079230A3 (en) Haplotypes of the ugt1a1 gene
Mani UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof
WO2002026764A3 (en) Haplotypes of the ccr6 gene
WO2001023603A3 (en) Human fmo3 gene mutations and polymorphisms, and uses thereof
WO2002012498A3 (en) Haplotypes of the isl1 gene
WO2001077363A3 (en) Haplotypes of the impdh2 gene
WO2002026766A3 (en) Haplotypes of the sstr4 gene
EP1391458A3 (en) Novel method for producing 5-aryloxymethyl-2-oxazolidinones
WO2002053579A3 (en) Haplotypes of the fmo2 gene
WO2002022652A8 (en) Haplotypes of the slc18a2 gene
WO2002012562A3 (en) Haplotypes of the pla2g1b gene
WO2002038587A3 (en) Haplotypes of the grm8 gene
WO2001090118A3 (en) Haplotypes of the edn2 gene
WO2001087906A3 (en) Haplotypes of the stk11 gene
WO2002020556A3 (en) Haplotypes of the gpr68 gene
WO2002002580A3 (en) Haplotypes of the etfb gene
WO2002032930A3 (en) Haplotypes of the scya21 gene
WO2002062820A3 (en) Haplotypes of the cyp27b1 gene